Urokinase specification

  Urokinase pharmacological action

  the goods can direct effects on endogenous fibrinolysis system into a fibrinolytic enzyme catalytic cracking fibrinolytic enzyme, which can not only degradation of fibrin clot, also can degrade fibrinogen in blood, and clotting factor Ⅴ and blood coagulation factor Ⅷ etc, so as to play a role of thrombolysis. The product has quick effect and good effect on newly formed thrombus. It can also improve the activity of ADP enzyme, inhibit ADP-induced platelet aggregation and prevent thrombosis. After intravenous infusion, the fibrinolytic activity in the patients was significantly increased. 

Plasminogen activity returned to progen levels a few hours after withdrawal, but a decrease in plasma fibrin or fibrinogen levels and an increase in their degradation products lasted 12 to 24 hours. This product showed a significant correlation between thrombolytic effect and drug dose and time window of administration. The toxicity of this product was very low, and half of the deaths from intravenous injection in mice were greater than 1 million ius/kg body weight. There were no obvious antigenicity, teratogenicity, carcinogenicity or mutagenicity. Anaphylaxis has rarely been reported in clinical practice. However, in view of its increased plasminogen activity and reduced circulation of unbound plasminogen and fibrin-bound plasminogen, there may be a serious risk of bleeding.